NYSE:JNJ - Johnson & Johnson Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $166.08
  • Forecasted Upside: 15.49 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$143.80
▼ -2.56 (-1.75%)
1 month | 3 months | 12 months
Get New Johnson & Johnson Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JNJ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JNJ

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$166.08
▲ +15.49% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $166.08, with a high forecast of $182.00 and a low forecast of $155.00. The average price target represents a 15.49% upside from the last price of $143.80.
Buy
The current consensus among 13 polled investment analysts is to buy stock in Johnson & Johnson. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/2/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/31/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/29/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/27/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/27/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/25/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020Raymond JamesReiterated RatingBuyLow
i
10/14/2020Credit Suisse GroupBoost Price TargetPositive ➝ Outperform$163.00 ➝ $168.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
10/14/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$168.00 ➝ $180.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
10/13/2020Credit Suisse GroupSet Price TargetBuy$163.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
9/4/2020Credit Suisse GroupReiterated RatingBuyMedium
i
Rating by Matt Miksic at Credit Suisse Group AG
8/19/2020Stifel NicolausDowngradeBuy ➝ HoldLow
i
8/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
7/20/2020Bank of AmericaReiterated RatingBuyLow
i
7/20/2020Independent ResearchUpgradeHold ➝ Buy$161.00 ➝ $164.00Low
i
7/17/2020Raymond JamesBoost Price TargetOutperform$157.00 ➝ $158.00Medium
i
7/17/2020CitigroupBoost Price TargetBuy$165.00 ➝ $170.00Low
i
7/15/2020SVB LeerinkReiterated RatingOutperformMedium
i
Rating by D. Antalffy at SVB Leerink LLC
4/29/2020Morgan StanleyBoost Price TargetOverweight$160.00 ➝ $170.00Low
i
Rating by David Lewis at Morgan Stanley
4/29/2020BarclaysBoost Price TargetOverweight$173.00 ➝ $182.00Low
i
Rating by Kristen Stewart at Barclays PLC
4/28/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
4/28/2020Credit Suisse GroupReiterated RatingBuy$161.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
4/28/2020UBS GroupDowngradeBuy ➝ Neutral$163.00 ➝ $160.00Medium
i
4/22/2020Wells Fargo & CompanyUpgradeHoldMedium
i
Rating by Larry Biegelsen at Wells Fargo & Company
4/22/2020Bank of AmericaUpgradeNeutral ➝ Buy$150.00 ➝ $175.00Low
i
4/15/2020Stifel NicolausBoost Price TargetHold$140.00 ➝ $155.00Medium
i
4/15/2020Wells Fargo & CompanyBoost Price TargetOverweight$150.00 ➝ $162.00Medium
i
4/15/2020CitigroupBoost Price TargetBuy$150.00 ➝ $165.00Medium
i
4/15/2020Raymond JamesBoost Price TargetOutperform$153.00 ➝ $157.00Low
i
4/15/2020Credit Suisse GroupBoost Price TargetOutperform$155.00 ➝ $161.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
4/9/2020Raymond JamesLower Price TargetOutperform$161.00 ➝ $153.00Low
i
4/8/2020SVB LeerinkLower Price TargetOutperform$172.00 ➝ $160.00High
i
4/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00High
i
Rating by Louise Chen at Cantor Fitzgerald
4/2/2020Wells Fargo & CompanyLower Price TargetOverweight$165.00 ➝ $150.00Medium
i
4/1/2020Stifel NicolausLower Price TargetHold$155.00 ➝ $140.00Low
i
3/27/2020Morgan StanleyLower Price TargetOverweight$170.00 ➝ $160.00Medium
i
Rating by David Lewis at Morgan Stanley
3/27/2020CitigroupLower Price TargetBuy$163.00 ➝ $150.00Low
i
3/27/2020ArgusReiterated RatingBuy$165.00 ➝ $155.00Low
i
3/6/2020Credit Suisse GroupLower Price TargetOutperform$170.00 ➝ $159.00Medium
i
Rating by Matt Miksic at Credit Suisse Group AG
3/4/2020CitigroupInitiated CoverageBuy$163.00Low
i
2/17/2020Credit Suisse GroupReiterated RatingBuy$170.00Medium
i
Rating by Matt Miksic at Credit Suisse Group AG
1/27/2020Credit Suisse GroupBoost Price TargetOutperform$163.00 ➝ $170.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
1/23/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
1/23/2020Raymond JamesBoost Price TargetOutperform$147.00 ➝ $161.00Low
i
1/9/2020Wells Fargo & CompanyBoost Price TargetOverweight$155.00 ➝ $165.00Low
i
12/31/2019Credit Suisse GroupReiterated RatingBuy$163.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
12/19/2019BarclaysUpgradeEqual Weight ➝ Overweight$140.00 ➝ $173.00Medium
i
Rating by Kristen Stewart at Barclays PLC
12/17/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$145.00 ➝ $170.00Low
i
11/27/2019Cantor FitzgeraldInitiated CoverageOverweight$160.00Low
i
Rating by L. Chen at Cantor Fitzgerald
11/19/2019Cantor FitzgeraldInitiated CoverageOverweight$160.00 ➝ $160.00Low
i
Rating by L. Chen at Cantor Fitzgerald
10/24/2019Credit Suisse GroupBoost Price Target$158.00 ➝ $163.00Low
i
10/16/2019Credit Suisse GroupBoost Price TargetOutperform$156.00 ➝ $158.00Medium
i
10/16/2019Wells Fargo & CompanyLower Price TargetOutperform$157.00 ➝ $155.00Medium
i
10/16/2019Atlantic SecuritiesUpgradeUnderweight ➝ NeutralMedium
i
10/14/2019Raymond JamesLower Price TargetOutperform$146.00 ➝ $145.00Low
i
10/11/2019Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$155.00Low
i
8/27/2019The Goldman Sachs GroupSet Price TargetBuy$169.00Medium
i
8/27/2019Morgan StanleyReiterated RatingEqual Weight$145.00High
i
8/27/2019Credit Suisse GroupSet Price TargetBuy$156.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
7/18/2019Credit Suisse GroupSet Price TargetBuy$156.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
7/17/2019Raymond JamesLower Price TargetOutperform$147.00 ➝ $146.00Low
i
7/16/2019Royal Bank of CanadaReiterated RatingBuyLow
i
7/16/2019Bank of AmericaReiterated RatingHold$150.00Low
i
7/12/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$156.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
6/21/2019BarclaysInitiated CoverageHold$140.00Low
i
Rating by Kristen Stewart at Barclays PLC
5/28/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ BuyHigh
i
5/16/2019Credit Suisse GroupBoost Price TargetOutperform$152.00 ➝ $156.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
5/6/2019Wells Fargo & CompanyReiterated RatingOutperform$152.00 ➝ $157.00Low
i
4/17/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$154.00 ➝ $157.00Low
i
4/17/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$151.00 ➝ $152.00Low
i
4/17/2019Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$134.00 ➝ $145.00Low
i
Rating by Scott Wang at Morgan Stanley
4/17/2019Raymond JamesBoost Price TargetOutperform ➝ Outperform$145.00 ➝ $147.00Low
i
2/25/2019CitigroupBoost Price TargetNeutral ➝ Neutral$139.00 ➝ $147.00Low
i
1/23/2019BarclaysReiterated RatingEqual Weight ➝ Equal Weight$137.00 ➝ $135.00High
i
1/14/2019Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$162.00 ➝ $152.00Low
i
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$153.00 ➝ $130.00Low
i
Rating by Scott Wang at Morgan Stanley
1/2/2019CitigroupLower Price TargetNeutral ➝ Neutral$148.00 ➝ $139.00Low
i
12/20/2018Morgan StanleySet Price TargetHold$140.00Low
i
Rating by Scott Wang at Morgan Stanley
10/22/2018CitigroupBoost Price TargetNeutral ➝ Neutral$137.00 ➝ $148.00Low
i
10/17/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$149.00 ➝ $152.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
10/17/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$144.00 ➝ $149.00Medium
i
10/17/2018Wells Fargo & CompanyReiterated RatingOutperform$155.00 ➝ $160.00Medium
i
10/17/2018HC WainwrightReiterated RatingBuyHigh
i
10/14/2018Credit Suisse GroupSet Price TargetBuy$149.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
9/14/2018Wells Fargo & CompanyReiterated RatingOutperform$160.00Low
i
7/15/2018Jefferies Financial GroupSet Price TargetBuy$145.00Medium
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
7/13/2018Credit Suisse GroupSet Price TargetBuy$151.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
7/12/2018The Goldman Sachs GroupUpgradeSell ➝ NeutralLow
i
6/27/2018Sanford C. BernsteinInitiated CoverageMarket Perform$129.00Low
i
6/12/2018Credit Suisse GroupSet Price TargetBuy$151.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
4/23/2018CitigroupLower Price TargetNeutral$146.00 ➝ $134.00Low
i
4/20/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$154.00 ➝ $151.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
4/18/2018Wells Fargo & CompanyReiterated RatingOutperform$160.00 ➝ $150.00High
i
4/18/2018Stifel NicolausLower Price TargetHold ➝ Hold$145.00 ➝ $135.00High
i
4/18/2018SVB LeerinkReiterated RatingOutperform$175.00 ➝ $160.00High
i
4/18/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyHigh
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
4/17/2018Credit Suisse GroupSet Price TargetBuy$154.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
4/17/2018The Goldman Sachs GroupSet Price TargetSell$134.00Low
i
4/13/2018Jefferies Financial GroupSet Price TargetBuy$153.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
4/10/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$148.00 ➝ $143.00Low
i
3/23/2018Jefferies Financial GroupSet Price TargetBuy$161.00Medium
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/27/2018CitigroupLower Price TargetNeutral ➝ Neutral$150.00 ➝ $146.00Medium
i
2/26/2018Jefferies Financial GroupSet Price TargetBuy$165.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
1/24/2018Stifel NicolausBoost Price TargetHold ➝ Hold$142.00 ➝ $145.00Low
i
1/24/2018BTIG ResearchReiterated RatingSell$110.00Low
i
1/22/2018Credit Suisse GroupSet Price TargetHold$154.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
1/12/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$155.00 ➝ $160.00Low
i
1/9/2018Royal Bank of CanadaReiterated RatingBuyLow
i
1/2/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
i
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$161.00Medium
i
10/23/2017CitigroupBoost Price TargetBuy$140.00 ➝ $149.00N/A
i
10/19/2017Credit Suisse GroupSet Price TargetOutperform$147.00 ➝ $154.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
10/18/2017BarclaysBoost Price TargetEqual Weight$140.00 ➝ $148.00N/A
i
10/18/2017CowenReiterated RatingOutperform$147.00 ➝ $155.00N/A
i
Rating by Josh Jennings at Cowen Inc
10/18/2017Morgan StanleyReiterated RatingHold$140.00 ➝ $145.00N/A
i
Rating by Scott Wang at Morgan Stanley
10/18/2017ArgusBoost Price TargetBuy ➝ Positive$145.00 ➝ $165.00N/A
i
10/18/2017Wells Fargo & CompanyReiterated RatingOutperform$149.00 ➝ $155.00N/A
i
10/18/2017BMO Capital MarketsReiterated RatingOutperform ➝ Positive$145.00 ➝ $152.00N/A
i
10/18/2017Stifel NicolausBoost Price TargetHold ➝ Hold$140.00 ➝ $142.00N/A
i
10/18/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$144.00 ➝ $147.00N/A
i
10/18/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$150.00 ➝ $165.00N/A
i
10/16/2017Jefferies Financial GroupBoost Price TargetBuy$157.00 ➝ $160.00N/A
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
10/11/2017Jefferies Financial GroupUpgradeHold ➝ Buy$145.00 ➝ $157.00N/A
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
10/9/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$140.00 ➝ $149.00N/A
i
10/6/2017CowenSet Price TargetBuy$147.00N/A
i
Rating by Josh Jennings at Cowen Inc
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00Low
i
9/30/2017UBS GroupReiterated RatingBuy$148.00Low
i
9/25/2017CitigroupInitiated CoverageNeutral ➝ Neutral$140.00Low
i
9/20/2017The Goldman Sachs GroupDowngradeNeutral ➝ Sell$125.00 ➝ $130.00Low
i
9/1/2017BMO Capital MarketsReiterated RatingBuy$145.00N/A
i
8/31/2017UBS GroupReiterated RatingBuy$148.00Low
i
8/24/2017UBS GroupReiterated RatingUnderweightLow
i
8/24/2017CowenSet Price TargetBuy$147.00Low
i
Rating by Steve Scala at Cowen Inc
8/16/2017JPMorgan Chase & Co.Boost Price TargetOverweight$140.00 ➝ $148.00Low
i
8/15/2017Jefferies Financial GroupSet Price TargetHold$145.00Low
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
8/4/2017Credit Suisse GroupReiterated RatingBuyLow
i
7/21/2017Alembic Global AdvisorsDowngradeNeutral ➝ UnderweightLow
i
7/21/2017Atlantic SecuritiesDowngradeNeutral ➝ Underweight$113.00Low
i
7/21/2017BTIG ResearchDowngradeNeutral ➝ Sell$110.00Low
i
7/20/2017Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$148.00Medium
i
7/19/2017UBS GroupReiterated RatingBuy$136.00 ➝ $148.00Low
i
7/14/2017Jefferies Financial GroupReiterated RatingHold$140.00 ➝ $145.00Low
i
7/12/2017Royal Bank of CanadaReiterated RatingBuy$138.00Medium
i
7/6/2017Wells Fargo & CompanyReiterated RatingMarket Perform$132.00 ➝ $135.00Low
i
7/5/2017Morgan StanleyBoost Price TargetOverweight$135.00 ➝ $140.00Low
i
6/16/2017Jefferies Financial GroupReiterated RatingHold$140.00Medium
i
6/15/2017Royal Bank of CanadaReiterated RatingBuy$128.00Medium
i
6/13/2017CowenReiterated RatingOutperform$143.00Low
i
Rating by Josh Jennings at Cowen Inc
6/2/2017BMO Capital MarketsReiterated RatingBuy$132.00Low
i
5/21/2017BTIG ResearchReiterated RatingHoldLow
i
5/19/2017Morgan StanleyReiterated RatingEqual Weight$130.00 ➝ $135.00Low
i
5/19/2017CowenReiterated RatingBuy$138.00 ➝ $143.00Low
i
5/18/2017Stifel NicolausReiterated RatingHold ➝ Hold$124.00 ➝ $128.00Low
i
5/15/2017UBS GroupReiterated RatingBuy$136.00N/A
i
5/15/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$123.64 ➝ $140.00High
i
5/14/2017Jefferies Financial GroupReiterated RatingHold$140.00 ➝ $135.00High
i
4/19/2017BTIG ResearchReiterated RatingHoldLow
i
4/17/2017BarclaysReiterated RatingEqual Weight$125.00 ➝ $130.00Low
i
3/11/2017Jefferies Financial GroupReiterated RatingHold$125.00 ➝ $132.00N/A
i
1/26/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$112.28 ➝ $112.80N/A
i
1/25/2017UBS GroupLower Price TargetBuy$142.00 ➝ $141.00N/A
i
Rating by steven fisher at UBS Group AG
1/25/2017Royal Bank of CanadaLower Price TargetOutperform$133.00 ➝ $128.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
1/25/2017The Goldman Sachs GroupLower Price TargetNeutral$120.00 ➝ $115.00N/A
i
1/20/2017Jefferies Financial GroupBoost Price TargetHold$110.00 ➝ $120.00N/A
i
1/6/2017Royal Bank of CanadaReiterated RatingBuy$133.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
1/5/2017Jefferies Financial GroupReiterated RatingHold$107.00 ➝ $110.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
12/20/2016Credit Suisse GroupReiterated RatingHoldN/A
i
12/20/2016Jefferies Financial GroupReiterated RatingHold$107.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
11/29/2016BarclaysDowngradeOverweight ➝ Equal Weight$130.00 ➝ $125.00N/A
i
Rating by Geoff Meacham at Barclays PLC
11/28/2016Bank of AmericaReiterated RatingHold$126.00N/A
i
11/28/2016UBS GroupReiterated RatingBuy$144.00N/A
i
Rating by steven fisher at UBS Group AG
11/9/2016Royal Bank of CanadaSet Price TargetBuy$133.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/A
i
10/21/2016ArgusReiterated RatingBuy$145.00N/A
i
10/19/2016UBS GroupReiterated RatingBuy$137.00 ➝ $144.00N/A
i
Rating by steven fisher at UBS Group AG
9/28/2016UBS GroupReiterated RatingBuy$137.00N/A
i
Rating by steven fisher at UBS Group AG
9/20/2016UBS GroupReiterated RatingBuy$137.00N/A
i
Rating by steven fisher at UBS Group AG
9/19/2016Credit Suisse GroupReiterated RatingNeutral$123.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
9/13/2016Jefferies Financial GroupLower Price TargetHold$119.00 ➝ $115.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
9/11/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
9/7/2016BTIG ResearchReiterated RatingNeutralN/A
i
Rating by Dane Leone at BTIG Research
9/7/2016UBS GroupReiterated RatingBuyN/A
i
Rating by steven fisher at UBS Group AG
8/25/2016BTIG ResearchReiterated RatingNeutralN/A
i
Rating by Dane Leone at BTIG Research
8/22/2016UBS GroupReiterated RatingBuyN/A
i
Rating by steven fisher at UBS Group AG
8/19/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$142.00N/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
8/4/2016Jefferies Financial GroupBoost Price TargetHold$113.00 ➝ $119.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/22/2016UBS GroupReiterated RatingBuy$126.00 ➝ $137.00N/A
i
Rating by Matt Miksic at UBS Group AG
7/21/2016Deutsche Bank AktiengesellschaftReiterated RatingHold$125.00 ➝ $142.00N/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
7/20/2016Royal Bank of CanadaReiterated RatingOutperform$125.00 ➝ $133.00N/A
i
7/20/2016SVB LeerinkReiterated RatingOutperform$125.00 ➝ $140.00N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
7/20/2016BMO Capital MarketsReiterated RatingOutperform$132.00N/A
i
7/20/2016Royal Bank of CanadaBoost Price TargetOutperform$125.00 ➝ $133.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
7/15/2016UBS GroupReiterated RatingBuy$126.00N/A
i
Rating by Matt Miksic at UBS Group AG
7/14/2016Jefferies Financial GroupBoost Price TargetHold$109.00 ➝ $113.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/11/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Larry Biegelsen at Wells Fargo & Company
7/10/2016BarclaysReiterated RatingOverweight$120.00 ➝ $125.00N/A
i
6/16/2016UBS GroupReiterated RatingBuyN/A
i
Rating by Matt Miksic at UBS Group AG
6/14/2016Jefferies Financial GroupReiterated RatingHold$108.00 ➝ $109.00N/A
i
6/13/2016The Goldman Sachs GroupSet Price TargetNeutral$121.00N/A
i
Rating by Jami Rubin at The Goldman Sachs Group, Inc.
6/6/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Larry Biegelsen at Wells Fargo & Company
6/3/2016BTIG ResearchReiterated RatingNeutralN/A
i
Rating by Dane Leone at BTIG Research
5/22/2016UBS GroupReiterated RatingBuyN/A
i
Rating by Matt Miksic at UBS Group AG
5/22/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
5/22/2016BTIG ResearchReiterated RatingHoldN/A
i
Rating by Dane Leone at BTIG Research
5/20/2016Raymond JamesReiterated RatingOutperform$120.00N/A
i
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/A
i
5/19/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
5/19/2016Bank of AmericaReiterated RatingHoldN/A
i
Rating by Bob Hopkins at Bank of America Co.
5/19/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by Sharon Stein at Morgan Stanley
5/19/2016Credit Suisse GroupReiterated RatingHold$112.00N/A
i
5/18/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Larry Biegelsen at Wells Fargo & Company
5/12/2016BTIG ResearchDowngradeBuy ➝ NeutralN/A
i
Rating by Dane Leone at BTIG Research
4/20/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
4/20/2016Piper Jaffray CompaniesBoost Price TargetNeutral$105.00 ➝ $106.00N/A
i
4/20/2016ArgusBoost Price TargetBuy$116.00 ➝ $130.00N/A
i
4/20/2016BarclaysReiterated RatingOverweight$115.00 ➝ $120.00N/A
i
Rating by Geoff Meacham at Barclays PLC
4/20/2016The Goldman Sachs GroupReiterated RatingNeutral$112.00 ➝ $114.00N/A
i
Rating by Jami Rubin at The Goldman Sachs Group, Inc.
4/19/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Larry Biegelsen at Wells Fargo & Company
4/17/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
4/17/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Glenn Novarro at Royal Bank of Canada
4/15/2016Royal Bank of CanadaBoost Price TargetOutperform$114.00 ➝ $122.00N/A
i
4/14/2016UBS GroupReiterated RatingBuyN/A
i
Rating by Matt Miksic at UBS Group AG
4/7/2016Wells Fargo & CompanyReiterated RatingBuy$115.00N/A
i
4/6/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
4/6/2016UBS GroupReiterated RatingBuyN/A
i
Rating by Matt Miksic at UBS Group AG
4/6/2016Societe GeneraleInitiated CoverageHold$113.00N/A
i
3/31/2016UBS GroupReiterated RatingBuyN/A
i
Rating by Matt Miksic at UBS Group AG
3/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$105.00N/A
i
3/15/2016Jefferies Financial GroupReiterated RatingHold$92.00 ➝ $99.00N/A
i
3/14/2016The Goldman Sachs GroupUpgradeSell ➝ Neutral$102.00 ➝ $112.00N/A
i
2/23/2016Royal Bank of CanadaReiterated RatingOutperform$114.00N/A
i
2/23/2016Morgan StanleyReiterated RatingEqual Weight$108.00N/A
i
2/10/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
2/10/2016BTIG ResearchReiterated RatingBuy$115.00N/A
i
Rating by Dane Leone at BTIG Research
2/4/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$117.00 ➝ $110.00N/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
1/27/2016BTIG ResearchReiterated RatingBuy$115.00N/A
i
1/27/2016The Goldman Sachs GroupReiterated RatingSell$100.00 ➝ $102.00N/A
i
1/27/2016Independent ResearchSet Price TargetNeutral$108.00N/A
i
1/27/2016SVB LeerinkReiterated RatingOutperform$115.00 ➝ $120.00N/A
i
1/25/2016Credit Suisse GroupReiterated RatingNeutralN/A
i
1/22/2016Raymond JamesReiterated RatingOutperform$108.00 ➝ $105.00N/A
i
1/21/2016Independent ResearchSet Price TargetNeutral$105.00N/A
i
1/14/2016Jefferies Financial GroupLower Price TargetHold$95.00 ➝ $92.00N/A
i
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$95.00N/A
i
12/7/2015Jefferies Financial GroupReiterated RatingHold$95.00N/A
i
12/2/2015BarclaysInitiated CoverageBuyN/A
i
Rating by Geoff Meacham at Barclays PLC
12/1/2015BarclaysUpgradeEqual Weight ➝ Overweight$101.00 ➝ $115.00N/A
i
(Data available from 11/23/2015 forward)
Johnson & Johnson logo
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $143.80
$143.62
$146.70

50 Day Range

MA: $145.51
$137.11
$151.84

52 Week Range

Now: $143.80
$109.16
$157.00

Volume

198,237 shs

Average Volume

8,102,420 shs

Market Capitalization

$378.56 billion

P/E Ratio

22.61

Dividend Yield

2.76%

Beta

0.69